Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study

Summary

This is a phase II, non-randomised, multicentre study to assess the safety and efficacy of the PD-L1 inhibitor, avelumab, in a previously untreated fit population of high risk stage II, stage III and stage IV classical Hodgkin lymphoma.

Timeline

Start

2019-09-27

Primary completion

2022-07-04

Completion

2025-05-30

Drugs

Indications